Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Trials
Published in: Trials 1/2017

Open Access 01-12-2017 | Study protocol

Lymphocyte opioid receptors as innovative biomarkers of osteoarthritic pain, for the assessment and risk management of opioid tailored therapy, before hip surgery, to prevent chronic pain and opioid tolerance/addiction development: OpMarkArt (Opioids-Markers-Arthroprosthesis) study protocol for a randomized controlled trial

Authors: Valentina Malafoglia, Monica Celi, Carolina Muscoli, Sara Ilari, Filomena Lauro, Luigino Antonio Giancotti, Chiara Morabito, Maurizio Feola, Umberto Tarantino, William Raffaeli

Published in: Trials | Issue 1/2017

Login to get access

Abstract

Background

The incidence of post-surgical chronic pain ranges between 20% and 40% in Europe. Osteoarthritis pain after prosthesis implantation is one of the most severe secondary syndromes, depending not only on surgery but also on organic changes before and after joints replacement. No data are available about risk factors. An excessive inflammatory response plays a central role but a best therapy is not defined yet. It is not clear whether opioid administration could influence post-surgical pain and lead to tolerance or addiction. Interestingly, the immune system, together with the nervous and peptidergic ones, is involved in hypersensibility. The connection across the three biological systems lies in the presence of opioid receptors on immune cells surface. Here, we show a method to analyze whether opioids could modulate lymphocytes, by proposing opioid receptors as biological markers to prevent chronic pain and opioid tolerance or addiction after hip surgery.

Methods/design

After institutional independent ethics committee approval, 60 patients, in pain and undergoing hip surgery, will be enrolled in a single-blind, randomized, phase IV, pilot study. Pain treatment will be selected inside a class of non-steroidal anti-inflammatory drugs (NAISDs) or paracetamol or a class of opioids, into three medication arms: 25 mg tapentadol twice daily; 75 mg tapentadol twice daily; NSAIDs or paracetamol in accordance with surgeon’s custom. For each group, we will collect blood samples before, during and after surgery, to apply molecular analysis. We will perform lymphocyte opioid receptors genes and proteins expression and functional analysis. Data will be statistically analyzed.

Discussion

This project has the potential to obtain a personalized diagnostic kit, by considering lymphocyte opioid receptors as biological markers. Starting from a simple blood sample, it will be possible to decide the best therapy for a single patient. Using a noninvasive approach, we expect to fix a daily standard dose and timing, before and after surgery, to bypass hip chronic pain and the insurgence of tolerance or addiction. The analysis of opioid receptors sensitivity will help to identify the best drug administration in each specific case (tailored therapy).

Trial registration

ISRCTN, ISRCTN12559751. Retrospectively registered on 23 May 2017.
Appendix
Available only for authorised users
Literature
1.
Kehlet H, Jensen TS, Woolf CJ. Persistent postsurgical pain: risk factors and prevention. Lancet. 2006;367:1618–25.CrossRefPubMed
2.
3.
Lam YF, Chan PK, Fu H, Yan CH, Chiu KY. A review of the clinical approach to persistent pain following total hip replacement. Hong Kong Med J. 2016;22(6):600–7.PubMed
4.
Fuzier R, Rousset J, Bataille B, Salces-y-Nédéo A, Maguès JP. One half of patients reports persistent pain three months after orthopaedic surgery. Anaesth Crit Care Pain Med. 2015;34(3):159–64.CrossRefPubMed
5.
Laufenberg-Feldmann R, Kappis B, Mauff S, Schmidtmann I, Ferner M. Prevalence of pain 6 months after surgery: a prospective observational study. BMC Anesthesiol. 2016;16(1):91.CrossRefPubMedPubMedCentral
6.
Elvemo NA, Nilsen KB, Landrø NI, Borchgrevink PC, Håberg AK. Patients with chronic pain lack somatic markers during decision-making. J Pain Res. 2014;7:425–37.PubMedPubMedCentral
7.
Erlenwein J, Müller M, Falla D, Przemeck M, Pfingsten M, Budde S, Quintel M, Petzke F. Clinical relevance of persistent postoperative pain after total hip replacement - a prospective observational cohort study. J Pain Res. 2017;10:2183-193.
8.
Pinho-Ribeiro FA, Verri Jr WA, Chiu IM. Nociceptor sensory neuron-immune interactions in pain and inflammation. Trends Immunol. 2016;38(1):5–19.CrossRefPubMed
9.
Ballantyne JC. Assessing the prevalence of opioid misuse, abuse, and addiction in chronic pain. Pain. 2015;156(4):567–8.CrossRefPubMed
10.
Liang X, Liu R, Chen C, Ji F, Li T. Opioid system modulates the immune function: a review. Transl Perioper Pain Med. 2016;1(1):5–13.PubMedPubMedCentral
11.
Provinciali M, Di Stefano G, Raffaeli W, Pari G, Desiderio F, Fabris N. Evaluation of NK and LAK cell activities in neoplastic patients during treatment with morphine. Intern J Neuroscience. 1991;59:127–33.CrossRef
12.
Provinciali M, Di Stefano G, Stronati S, Raffaeli W, Pari G, Fabris N. Role of prolactin in the modulation of NK and LAK cell activity after short or long-term morphine administration in neoplastic patients. Int J Immunopharmac. 1996;18:577–86.CrossRef
13.
Raffaeli W. Sistema immunitario ed analgesici. Minerva Anestesiol. 1999;65(91):181–3.
14.
Raffaeli W, Salmosky-Dekel BG. Biological consequences of long-term intrathecal administration of opioids. Minerva Anestesiol. 2005;71:475–8.
15.
Raffaeli W. Oppiacei e sistema neuroimmunoendocrino. In: Amadori D, Corli O, de Conno F, Maltoni M, Zucco F, editors. Libro Italiano di Cure Palliative. Vermezzo: Polletto Editore; 2003.
16.
Campana G, Sarti D, Spampinato S, Raffaeli W. Long-term intrathecal morphine and bupivacaine upregulate MOR gene expression in lymphocytes. Int Immunopharmacol. 2010;10(9):1149–52.CrossRefPubMed
17.
18.
Ruhe AK, Frosch M, Wager J, Linder R, Pfenning I, Sauerland D, Zernikow B. Health care utilization and cost in children and adolescents with chronic pain: analysis of health care claims data one year before and after intensive interdisciplinary pain treatment. Clin J Pain. 2017;33(9):767–76.CrossRefPubMed
19.
Hecke V, Torrance N, Smith BH. Chronic pain epidemiology and its clinical relevance. Br J Anaesth. 2013;111(1):13–8.CrossRefPubMed
20.
Young Casey C, Greenberg MA, Nicassio PM, Harpin RE, Hubbard D. Transition from acute to chronic pain and disability: a model including cognitive, affective, and trauma factors. Pain. 2008;134(1–2):69–79.CrossRefPubMed
21.
22.
Jungquist CR, Correll DJ, Fleisher LA, Gross J, Gupta R, Pasero C, Stoelting R, Polomano R. Avoiding adverse events secondary to opioid-induced respiratory depression: implications for nurse executives and patient safety. J Nurs Adm. 2016;46(2):87–94.CrossRefPubMed
23.
Brush DE. Complications of long-term opioid therapy for management of chronic pain: the paradox of opioid-induced hyperalgesia. J Med Toxicol. 2012;8(4):387–92.CrossRefPubMedPubMedCentral
24.
Morgan MM, Christie MJ. Analysis of opioid efficacy, tolerance, addiction and dependence from cell culture to human. Br J Pharmacol. 2011;164(4):1322–34. Review.CrossRefPubMedPubMedCentral
25.
Brack A, Rittner HL, Stein C. Immunosuppressive effects of opioids – clinical relevance. J Neuroimmune Pharmacol. 2011;6(4):490–502. Review.CrossRefPubMed
26.
Levy D, Burstein R, Kainz V, Jakubowski M, Strassman AM. Mast cell degranulation activates a pain pathway underlying migraine headache. Pain. 2007;130:166–76.CrossRefPubMedPubMedCentral
27.
Lewin GR, Rueff A, Mendell LM. Peripheral and central mechanisms of NGF-induced hyperalgesia. Eur J Neurosci. 1994;6:1903–12.CrossRefPubMed
28.
29.
Kiguchi N, Maeda T, Kobayashi Y, Fukazawa Y, Kishioka S. Macrophage inflammatory protein-1α mediates the development of neuropathic pain following peripheral nerve injury through interleukin-1β up-regulation. Pain. 2010;149:305–15.CrossRefPubMed
30.
Rutkowski MD, Pahl JL, Sweitzer S, van Rooijen N, DeLeo JA. Limited role of macrophages in generation of nerve injury-induced mechanical allodynia. Physiol Behav. 2000;71:225–35.CrossRefPubMed
31.
32.
Ting E, Guerrero AT, Cunha TM, Verri Jr WA, Taylor SM, Woodruff TM, Cunha FQ, Ferreira SH. Role of complement C5a in mechanical inflammatory hypernociception: potential use of C5a receptor antagonists to control inflammatory pain. Br J Pharmacol. 2008;153:1043–53.CrossRefPubMed
33.
Li M, Peake PW, Charlesworth JA, Tracey DJ, Moalem-Taylor G. Complement activation contributes to leukocyte recruitment and neuropathic pain following peripheral nerve injury in rats. Eur J Neurosci. 2007;26:3486–500.CrossRefPubMed
34.
Jang JH, Clark JD, Li X, Yorek MS, Usachev YM, Brennan TJ. Nociceptive sensitization by complement C5a and C3a in mouse. Pain. 2010;148:343–52.CrossRefPubMed
35.
Wining CM, Sloane EM, Schoeniger DK, Milligan ED, Martin D, Marsh H, Maier SF, Watkins LR. Activation of the spinal cord complement cascade might contribute to mechanical allodynia induced by three animal models of spinal sensitization. J Pain. 2005;6:174–83.CrossRef
36.
Moalem G, Xu K, Yu L. T lymphocytes play a role in neuropathic pain following peripheral nerve injury in rats. Neuroscience. 2004;129:767–77.CrossRefPubMed
37.
Cui JG, Holmin S, Mathiesen T, Meyerson BA, Linderoth B. Possible role of inflammatory mediators in tactile hypersensitivity in rat mode mononeuropathy. Pain. 2000;88:239–48.CrossRefPubMed
38.
Costigan M, Moss A, Latremoliere A, Johnston C, Verma-Gandhu M, Herbert TA, Barrett L, Brenner GJ, Vardeh D, Woolf CJ, Fitzgerald M. T-cell infiltration and signaling in the adult dorsal spinal cord is a major contributor to neuropathic pain-like hypersensitivity. J Neurosci. 2009;29:14415–22.CrossRefPubMedPubMedCentral
39.
Cao L, DeLeo JA. CNS-infiltrating CD4+ T lymphocytes contribute to murine spinal nerve transection-induced neuropathic pain. Eur J Immunol. 2008;38:448–58.CrossRefPubMedPubMedCentral
40.
Raffaeli W, Pari C, Corvetta A, Sarti D, Di Sabatino V, Biasi G, Galeazzi M. Oxycodone/acetaminophen at low dosage: an alternative pain treatment for patients with rheumatoid arthritis. J Opioid Manag. 2010;6(1):40–6.CrossRefPubMed
41.
42.
43.
Chan AW, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, Dickersin K, Hróbjartsson A, Schulz KF, Parulekar WR, Krleza-Jeric K, Laupacis A, Moher D. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586.CrossRefPubMedPubMedCentral
Metadata
Title
Lymphocyte opioid receptors as innovative biomarkers of osteoarthritic pain, for the assessment and risk management of opioid tailored therapy, before hip surgery, to prevent chronic pain and opioid tolerance/addiction development: OpMarkArt (Opioids-Markers-Arthroprosthesis) study protocol for a randomized controlled trial
Authors
Valentina Malafoglia
Monica Celi
Carolina Muscoli
Sara Ilari
Filomena Lauro
Luigino Antonio Giancotti
Chiara Morabito
Maurizio Feola
Umberto Tarantino
William Raffaeli
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Trials / Issue 1/2017
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-017-2363-z

Other articles of this Issue 1/2017

Trials 1/2017 Go to the issue

Study protocol

The effectiveness of a skin care program for the prevention of contact dermatitis in health care workers (the Healthy Hands Project): study protocol for a cluster randomized controlled trial

Study protocol

Benefit of dual-chamber pacing with Closed Loop Stimulation in tilt-induced cardio-inhibitory reflex syncope (BIOSync trial): study protocol for a randomized controlled trial

Study protocol

Effectiveness of an intervention to improve supportive care for family caregivers of patients with lung cancer: study protocol for a randomized controlled trial

Erratum

Erratum to: Optimizing adalimumab treatment in psoriasis with concomitant methotrexate (OPTIMAP): study protocol for a pragmatic, single-blinded, investigator-initiated randomized controlled trial

Study protocol

Randomized study exploring the combination of radiotherapy with two types of acupuncture treatment (ROSETTA): study protocol for a randomized controlled trial

Study protocol

RETRACTED ARTICLE: Esoteric Connective Tissue Therapy for chronic low back pain to reduce pain, and improve functionality and general well-being compared with physiotherapy: study protocol for a randomised controlled trial